> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# 3 No-Longer-Marketed NDAs Withdrawn
- URL: https://www.fdaweb.com/3-no-longer-marketed-ndas-withdrawn/
- Published: 2024-05-29T12:00:00.000Z
- Updated: 2026-09-14T14:32:03.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5157072

Federal Register notice: FDA is withdrawing approval of three NDAs from multiple applicants after they notified the agency that the products were no longer marketed and requested their withdrawal. The products are:

- Bayer Healthcare’s Cipro in Dextrose 5% in plastic container (ciprofloxacin) Injectable, 200 mg/100 mL and 400 mg/200 mL
- Bayer’s Cipro XR (ciprofloxacin hydrochloride) extended-release tablet, 287.5 mg base
- LG Chem Ltd.’s Factive (gemifloxacin mesylate) tablet, 320 mg base.

To view the notice, click [here](https://www.govinfo.gov/content/pkg/FR-2024-05-29/pdf/2024-11721.pdf?ref=fdaweb.com).